Frontline BioVentures
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Private Equity, Venture Capital
Stage Focus
Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, China
Industries Focus
- Healthcare
- Pharmaceuticals
- Medical Devices
- Biotechnology
Investor Details Founded: 2012
Frontline BioVentures is a China-based venture capital firm specializing in investments in innovative life science companies. The firm focuses on businesses within strategic life science and technology areas promoted by the Chinese government. Frontline BioVentures manages two funds: a RMB-denominated fund and a parallel USD fund, offering structural flexibility to best serve the needs of its portfolio companies.
The firm's investment strategy encompasses various stages, including early-stage, Series A, Series B, growth, late-stage, and pre-IPO investments. Geographically, Frontline BioVentures focuses on China and the United States, with a particular emphasis on sectors such as biotechnology, healthcare, medical devices, and pharmaceuticals.
In May 2017, Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital, a healthcare-focused investment group with extensive coverage across China and the U.S. This merger expanded the firm's portfolio and enhanced its capabilities in the life sciences sector.
Requirements
- Innovative life science companies
- Alignment with Chinese government-promoted strategic areas
- Potential for significant growth and market impact
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Innovent
- Hua Medicine
- BioKangtai
- Yikon Genomics
- Jiecheng Medical
- Neusoft Medical
Claim this Investor
Are you an official representative of Frontline BioVentures?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim